Lee Fairlie to Rifampin
This is a "connection" page, showing publications Lee Fairlie has written about Rifampin.
Connection Strength
0,705
-
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 Feb; 9(2):100-111.
Score: 0,215
-
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother. 2021 11 12; 76(12):3237-3246.
Score: 0,172
-
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
Score: 0,154
-
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
Score: 0,081
-
Challenges in recruiting children to a multidrug-resistant TB prevention trial. Int J Tuberc Lung Dis. 2021 10 01; 25(10):814-822.
Score: 0,043
-
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):201-204.
Score: 0,041